H. Lundbeck A/S

CPSE:HLUN B Stock Report

Market Cap: DKK 43.9b

H. Lundbeck Past Earnings Performance

Past criteria checks 5/6

H. Lundbeck has been growing earnings at an average annual rate of 19.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 6.6% per year. H. Lundbeck's return on equity is 14.4%, and it has net margins of 14.8%.

Key information

19.33%

Earnings growth rate

19.38%

EPS growth rate

Pharmaceuticals Industry Growth12.39%
Revenue growth rate6.59%
Return on equity14.41%
Net Margin14.82%
Next Earnings Update12 Nov 2025

Recent past performance updates

H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Supported By Other Strong Factors

May 23
H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Supported By Other Strong Factors

We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

Nov 21
We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

Recent updates

Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)

Oct 28
Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 16
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

H. Lundbeck A/S (CPH:HLUN B) Surges 25% Yet Its Low P/E Is No Reason For Excitement

May 28
H. Lundbeck A/S (CPH:HLUN B) Surges 25% Yet Its Low P/E Is No Reason For Excitement

H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Supported By Other Strong Factors

May 23
H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Supported By Other Strong Factors

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Reasonably Well

May 10
These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Reasonably Well

Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

Apr 13
Why Investors Shouldn't Be Surprised By H. Lundbeck A/S' (CPH:HLUN B) 29% Share Price Plunge

H. Lundbeck's (CPH:HLUN B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 13
H. Lundbeck's (CPH:HLUN B) Upcoming Dividend Will Be Larger Than Last Year's

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.95

Feb 23
H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.95

H. Lundbeck (CPH:HLUN B) Is Paying Out A Larger Dividend Than Last Year

Feb 09
H. Lundbeck (CPH:HLUN B) Is Paying Out A Larger Dividend Than Last Year

Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

Jan 26
Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

H. Lundbeck A/S' (CPH:HLUN B) Price In Tune With Earnings

Jan 04
H. Lundbeck A/S' (CPH:HLUN B) Price In Tune With Earnings
User avatar

Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth

Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.

We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

Nov 21
We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

Revenue & Expenses Breakdown

How H. Lundbeck makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CPSE:HLUN B Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2523,5213,4859,4324,375
31 Mar 2522,9513,2899,6164,223
31 Dec 2422,0043,1439,4333,954
30 Sep 2421,4412,6879,1624,361
30 Jun 2420,6712,5869,1733,654
31 Mar 2420,1562,4168,8233,571
31 Dec 2319,9122,2908,7063,457
30 Sep 2319,6142,4678,3623,381
30 Jun 2319,3812,4798,1153,471
31 Mar 2318,9182,3847,9493,612
31 Dec 2218,2461,9167,6893,754
30 Sep 2217,6191,6037,3983,846
30 Jun 2216,9131,2367,1273,947
31 Mar 2216,3981,1096,7683,884
31 Dec 2116,2991,3186,6253,820
30 Sep 2116,5211,8736,6983,711
30 Jun 2116,9711,9656,6803,655
31 Mar 2117,3812,1106,7202,999
31 Dec 2017,6721,5816,9123,753
30 Sep 2017,8189046,8123,760
30 Jun 2017,4901,2426,7443,538
31 Mar 2017,3661,5076,6724,039
31 Dec 1917,0362,3136,4133,116
30 Sep 1916,8113,0916,2123,214
30 Jun 1917,3093,3956,1433,302
31 Mar 1917,7663,6066,0613,313
31 Dec 1818,1173,9076,0393,277
30 Sep 1818,3133,8066,1203,069
30 Jun 1818,0283,6276,1742,903
31 Mar 1817,6083,2366,2982,765
31 Dec 1717,2342,6246,4822,705
30 Sep 1717,0072,5446,4282,769
30 Jun 1716,6071,9886,4622,839
31 Mar 1716,0751,6126,4242,887
31 Dec 1615,6341,2116,2932,967
30 Sep 1615,2022906,475-1,979
30 Jun 1614,923-1,2897,3203,196
31 Mar 1614,801-5,4277,5733,095
31 Dec 1514,594-5,6947,7623,097
30 Sep 1514,108-5,8797,8148,003
30 Jun 1513,625-4,6156,9282,666
31 Mar 1513,444-5656,5812,790
31 Dec 1413,468-1536,2982,689

Quality Earnings: HLUN B has high quality earnings.

Growing Profit Margin: HLUN B's current net profit margins (14.8%) are higher than last year (12.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HLUN B's earnings have grown by 19.3% per year over the past 5 years.

Accelerating Growth: HLUN B's earnings growth over the past year (34.8%) exceeds its 5-year average (19.3% per year).

Earnings vs Industry: HLUN B earnings growth over the past year (34.8%) exceeded the Pharmaceuticals industry 8.9%.

Return on Equity

High ROE: HLUN B's Return on Equity (14.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/11 09:45
End of Day Share Price 2025/11/11 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 36 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles PitmanBarclays
Emily FieldBarclays
Rosie TurnerBarclays